Q-omics provides the consensus-scored EMC3-AS1 profile across patient tissues and cancer cell-line models. EMC3-AS1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, EMC3-AS1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, EMC3-AS1 RNA expression shows 19,700 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight MESO, COAD, and DLBC as cancer lineages where EMC3-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EMC3-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EMC3-AS1 survival associations across molecular data types. EMC3-AS1 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EMC3-AS1 RNA expression–survival associations across cancer types. High EMC3-AS1 expression shows unfavorable associations in MESO, ACC, KIRC, KICH and LIHC, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for EMC3-AS1 RNA expression.
This table summarizes EMC3-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for EMC3-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EMC3-AS1 shows higher tumor expression in COAD, KIRP, LUAD, BLCA, LIHC and STAD. The COAD box plot shows higher EMC3-AS1 RNA expression in tumor versus normal tissue (log2 FC = +1.098, t-test p < 0.001).
This table shows molecular features associated with EMC3-AS1 in patient tissues and cancer cell lines. In patient samples, EMC3-AS1 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, EMC3-AS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS.
